LOG IN
SIGN UP
MARKET
RDHL
RDHL
Redhill Biopharm
NASDAQ
2.130
-0.070
-3.18%
Closed 16:00 06/02 EDT
OPEN
2.160
PREV CLOSE
2.200
HIGH
2.300
LOW
2.090
VOLUME
42.54K
TURNOVER
60.65K
52 WEEK HIGH
49.20
52 WEEK LOW
2.040
MARKET CAP
6.28M
P/E (TTM)
-0.0012
1D
5D
1M
3M
1Y
5Y
RedHill gains on decision to stop Phase 3 program for anti-bacterial agent
Seeking Alpha · 05/22 12:15
BRIEF-Redhill Provides Research And Development Update
Reuters · 05/22 11:52
Redhill Biopharma Has Terminated RHB-204's U.S. Phase 3 Study For Non-tuberculosis Mycobacteria Disease Due To Low Accrual Rate, And A Shift In Company's Resources To Advance Oral RHB-107's Late-Stage Development For COVID-19
Benzinga · 05/22 11:06
Redhill Biopharm: Report of foreign issuer
Press release · 05/22 11:05
RedHill Provides R&D Update
PR Newswire · 05/22 11:00
RedHill Biopharma Ends Phase 3 Trial of Non-Tuberculosis Mycobacteria Disease Drug to Focus on COVID-19 Program
RedHill Biopharma Ends Phase 3 Trial of Non-Tuberculosis Mycobacteria Disease Drug to Focus on COVID-19 Program
MT Newswires · 05/22 08:39
RedHill Biopharma gets Nasdaq non-compliance notice
Seeking Alpha · 05/16 09:33
Redhill Biopharma Receives Noncompliance Notice From Nasdaq
Redhill Biopharma Receives Noncompliance Notice From Nasdaq
MT Newswires · 05/16 07:41
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Webull offers kinds of RedHill Biopharma Ltd (ADR) stock information, including NASDAQ:RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.